Skip to main content
Erschienen in: Angiogenesis 2/2011

01.05.2011 | Original Paper

Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing’s sarcoma in the lung

verfasst von: Zhichao Zhou, Keri Schadler Stewart, Ling Yu, Eugenie S. Kleinerman

Erschienen in: Angiogenesis | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

An MHC-mismatch bone marrow (BM) transplant Ewing’s sarcoma mouse model was used to investigate whether BM cells participate in the vessel formation that support Ewing’s sarcoma lung metastasis. BM cells from H-2Kb/d donor mice were transplanted into sublethally irradiated H-2Kd recipient mice. Donor BM cells were identified using the H-2Kb marker. Engraftment was confirmed by identifying the H-2Kb IL-1β-type specific polymorphism. After engraftment highly lung metastatic TC71-PM4 cells were injected intravenously. Mice were sacrificed 10 weeks after tumor cell injection. Hematoxylin-and-eosin staining was performed to identify lung metastatic foci. These tumors were then evaluated using immunohistochemical analysis. H-2Kb-positive cells were found in lung metastases but not in normal lung, liver or spleen tissues. Injection of CM-Dil-labeled BM cells into tumor bearing and control mice showed that nonspecific organ migration occurred at 24 h, but that these cells were absent 1 week later in control mice. These data suggest that the migration of the H-2Kb BM cells to lung nodules was specific because these cells were observed 14 weeks after transplantation. Co-localization of H-2Kb and CD31 or VE-Cadherin demonstrated that some endothelial cells were BM-derived. Co-localization of H-2Kb and Desmin, smooth muscle actin (α-SMA) or PDGFR-β indicated that a fraction of pericytes was also BM-derived. These results suggest that BM cells participate in the vascular formation that supports the growth of Ewing’s sarcoma lung metastases. BM cells migrated to the metastatic tumor and differentiated into endothelial cells and pericytes. These data indicated that targeting this process may have therapeutic potential.
Literatur
1.
Zurück zum Zitat Weigelt B, Peterse JL, van ‘t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602PubMedCrossRef Weigelt B, Peterse JL, van ‘t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602PubMedCrossRef
2.
Zurück zum Zitat Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef
3.
Zurück zum Zitat Paulussen M, Ahrens S, Craft AW, Dunst J, Frohlich B, Jabar S, Rube C, Winkelmann W, Wissing S, Zoubek A et al (1998) Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing’s Sarcoma Studies patients. J Clin Oncol 16:3044–3052PubMed Paulussen M, Ahrens S, Craft AW, Dunst J, Frohlich B, Jabar S, Rube C, Winkelmann W, Wissing S, Zoubek A et al (1998) Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing’s Sarcoma Studies patients. J Clin Oncol 16:3044–3052PubMed
5.
Zurück zum Zitat Barker LM, Pendergrass TW, Sanders JE, Hawkins DS (2005) Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol 23:4354–4362PubMedCrossRef Barker LM, Pendergrass TW, Sanders JE, Hawkins DS (2005) Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol 23:4354–4362PubMedCrossRef
6.
Zurück zum Zitat Terek RM, Brien EW, Marcove RC, Meyers PA, Lane JM, Healey JH (1996) Treatment of femoral Ewing’s sarcoma. Cancer 78:70–78PubMedCrossRef Terek RM, Brien EW, Marcove RC, Meyers PA, Lane JM, Healey JH (1996) Treatment of femoral Ewing’s sarcoma. Cancer 78:70–78PubMedCrossRef
7.
Zurück zum Zitat Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA et al (2004) Treatment of metastatic Ewing’s sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children’s Cancer Group and Pediatric Oncology Group study. J Clin Oncol 22:2873–2876PubMedCrossRef Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA et al (2004) Treatment of metastatic Ewing’s sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children’s Cancer Group and Pediatric Oncology Group study. J Clin Oncol 22:2873–2876PubMedCrossRef
8.
Zurück zum Zitat Bolontrade MF, Zhou RR, Kleinerman ES (2002) Vasculogenesis plays a role in the growth of Ewing’s sarcoma in vivo. Clin Cancer Res 8:3622–3627PubMed Bolontrade MF, Zhou RR, Kleinerman ES (2002) Vasculogenesis plays a role in the growth of Ewing’s sarcoma in vivo. Clin Cancer Res 8:3622–3627PubMed
9.
Zurück zum Zitat Reddy K, Cao Y, Zhou Z, Yu L, Jia SF, Kleinerman ES (2008) VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculature. Angiogenesis 11:257–267PubMedCrossRef Reddy K, Cao Y, Zhou Z, Yu L, Jia SF, Kleinerman ES (2008) VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculature. Angiogenesis 11:257–267PubMedCrossRef
10.
Zurück zum Zitat Reddy K, Zhou Z, Schadler K, Jia SF, Kleinerman ES (2008) Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing’s tumor vessels. Mol Cancer Res 6:929–936PubMedCrossRef Reddy K, Zhou Z, Schadler K, Jia SF, Kleinerman ES (2008) Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing’s tumor vessels. Mol Cancer Res 6:929–936PubMedCrossRef
11.
Zurück zum Zitat Lee TH, Bolontrade MF, Worth LL, Guan H, Ellis LM, Kleinerman ES (2006) Production of VEGF165 by Ewing’s sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. Int J Cancer 119:839–846PubMedCrossRef Lee TH, Bolontrade MF, Worth LL, Guan H, Ellis LM, Kleinerman ES (2006) Production of VEGF165 by Ewing’s sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. Int J Cancer 119:839–846PubMedCrossRef
12.
Zurück zum Zitat Zhou Z, Reddy K, Guan H, Kleinerman ES (2007) VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing’s sarcoma tumors in vivo. Mol Cancer Res 5:1125–1132PubMedCrossRef Zhou Z, Reddy K, Guan H, Kleinerman ES (2007) VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing’s sarcoma tumors in vivo. Mol Cancer Res 5:1125–1132PubMedCrossRef
13.
Zurück zum Zitat Reddy K, Zhou Z, Jia SF, Lee TH, Morales-Arias J, Cao Y, Kleinerman ES (2008) Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing’s sarcoma tumor growth in the absence of vascular endothelial growth factor. Int J Cancer 123:831–837PubMedCrossRef Reddy K, Zhou Z, Jia SF, Lee TH, Morales-Arias J, Cao Y, Kleinerman ES (2008) Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing’s sarcoma tumor growth in the absence of vascular endothelial growth factor. Int J Cancer 123:831–837PubMedCrossRef
14.
Zurück zum Zitat Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES (2005) A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing’s sarcoma growth in a xenograft mouse model. Clin Cancer Res 11:2662–2669PubMedCrossRef Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES (2005) A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing’s sarcoma growth in a xenograft mouse model. Clin Cancer Res 11:2662–2669PubMedCrossRef
15.
Zurück zum Zitat Yu L, Su B, Hollomon M, Deng Y, Facchinetti V, Kleinerman ES (2010) Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing’s sarcomas. Cancer Res 70:1334–1343PubMedCrossRef Yu L, Su B, Hollomon M, Deng Y, Facchinetti V, Kleinerman ES (2010) Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing’s sarcomas. Cancer Res 70:1334–1343PubMedCrossRef
16.
Zurück zum Zitat Jia SF, Worth LL, Kleinerman ES (1999) A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 17:501–506PubMedCrossRef Jia SF, Worth LL, Kleinerman ES (1999) A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 17:501–506PubMedCrossRef
17.
Zurück zum Zitat Jacob CO, Mykytyn K, Tashman N (1993) DNA polymorphism in cytokine genes based on length variation in simple-sequence tandem repeats. Immunogenetics 38:251–257PubMedCrossRef Jacob CO, Mykytyn K, Tashman N (1993) DNA polymorphism in cytokine genes based on length variation in simple-sequence tandem repeats. Immunogenetics 38:251–257PubMedCrossRef
18.
Zurück zum Zitat Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N, Mittal V (2009) Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 1796:33–40PubMed Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N, Mittal V (2009) Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 1796:33–40PubMed
19.
Zurück zum Zitat Taylor M, Rossler J, Geoerger B, Laplanche A, Hartmann O, Vassal G, Farace F (2009) High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res 15:4561–4571PubMedCrossRef Taylor M, Rossler J, Geoerger B, Laplanche A, Hartmann O, Vassal G, Farace F (2009) High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res 15:4561–4571PubMedCrossRef
20.
Zurück zum Zitat Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, Hicklin DJ, Kleinerman ES (2007) Suppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 13:4867–4873PubMedCrossRef Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, Hicklin DJ, Kleinerman ES (2007) Suppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 13:4867–4873PubMedCrossRef
21.
Zurück zum Zitat Aiuti A, Webb IJ, Bleul C, Springer T, Gulierrez-Ramos JC (1997) The chemmokine SDF-1 ia a chemoattractan for human CD34+ hemotopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 185:111–120PubMedCrossRef Aiuti A, Webb IJ, Bleul C, Springer T, Gulierrez-Ramos JC (1997) The chemmokine SDF-1 ia a chemoattractan for human CD34+ hemotopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 185:111–120PubMedCrossRef
22.
Zurück zum Zitat Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, VandenBerg S, Johnson RS, Werb Z, Bergers G (2008) HIF1a induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206–220PubMedCrossRef Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, VandenBerg S, Johnson RS, Werb Z, Bergers G (2008) HIF1a induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206–220PubMedCrossRef
23.
Zurück zum Zitat Erier JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le Q, Giaccia AJ (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15:35–44CrossRef Erier JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le Q, Giaccia AJ (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15:35–44CrossRef
24.
Zurück zum Zitat Gao D, Mittal V (2009) The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol Med 15:333–343PubMedCrossRef Gao D, Mittal V (2009) The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol Med 15:333–343PubMedCrossRef
Metadaten
Titel
Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing’s sarcoma in the lung
verfasst von
Zhichao Zhou
Keri Schadler Stewart
Ling Yu
Eugenie S. Kleinerman
Publikationsdatum
01.05.2011
Verlag
Springer Netherlands
Erschienen in
Angiogenesis / Ausgabe 2/2011
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-010-9196-7

Weitere Artikel der Ausgabe 2/2011

Angiogenesis 2/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.